The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study


Disclosures: Eric van Roon received travel expenses from Boehringer Ingelheim. Mels Hoogendoorn received travel expenses from Brystol-Myers Squibb and has a consulting or advisory role for Novartis. The other authors have no conflicts of interest to disclose.

Contributions: BO, RA, MHH, RK, NV, JV, ER and MH designed the research study; BO, RA and JV collected the data; NV performed the statistical analysis; BO wrote the manuscript and all authors critically revised and approved the submitted manuscript.